SCHEMBL24022745

SCHEMBL24022745

CC(=O)Nc1cc(F)cc(-c2nncnn2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 1/20 0.49
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 5/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ MEN1 O00255 5/20 0.39
▸ KMT2A Q03164 5/20 0.39
▸ KDM4E B2RXH2 4/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ HPGD P15428 3/20 0.39
▸ RXFP1 Q9HBX9 2/20 0.39
▸ GAA P10253 1/20 0.38
▸ PLK4 O00444 1/20 0.38
▸ PAK4 O96013 1/20 0.38
▸ NTRK1 P04629 1/20 0.38
▸ PTK2 Q05397 1/20 0.38
▸ TBK1 Q9UHD2 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ ADORA2A P29274 1/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24334074 0.84 CYP3A4 (0.43) MAP4K4LMNAMAPTMEN1KMT2A
SCHEMBL24334059 0.82 TP53 (0.44) MAP4K4MEN1KMT2AKDM4EALDH1A1
SCHEMBL24022757 0.82 MAPT (0.42) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL29582523 0.81 CYP17A1 (0.40) MAP4K4HDAC3HDAC1HDAC2
SCHEMBL13414535 0.76 LMNA (0.58) MAP4K4LMNAMAPTIDO1MEN1
SCHEMBL7978815 0.76 LMNA (0.58) MAP4K4LMNAMAPTIDO1MEN1
SCHEMBL22044402 0.74 KDM4E (0.41) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL24022747 0.74 MAP4K4 (0.49) MAP4K4HDAC2
SCHEMBL22044265 0.72 HCAR1 (0.48) TSHR
SCHEMBL23412709 0.72 LMNA (0.48) MAP4K4LMNAMAPTIDO1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119359-A1 NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING Københavns Universitet (DK) 2022-04-21 — — US disclosed
WO-2021228992-A1 NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY RIGSHOSPITALET (DK) 2021-11-18 — — WO disclosed
EP-3909944-A1 NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY Rigshospitalet (DK) 2021-11-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119359-A1 NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING RTN3, RXFP3, TAAR5 MAP4K4 4162/4885LMNA 1678/4885MAPT 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback